23andMe as founded in 2006 by Anne Wojcicki, Linda Avey, Paul Cusenza in 2006. 23andMe provides health and ancestry information based on analysis of a customer’s DNA obtained using a saliva collection kit. Reports are accessed in an online account. Genetic information is kept in separate databases from personally identifiable information to protect user identity.
In 2013 the FDA ordered the company to stop providing information about their customers’ health risks. The FDA later decided to allow 23andMe to tell customers their risks for developing ten medical conditions including Parkinson’s disease, late-onset Alzheimer’s disease and Bloom syndrome.
Each customer can opt in or out for letting 23andMe use their genetic information for research. In 2017 the data from its 2 million customers was considered the largest collection of gene-linked data. 23andMe has its own drug development team lead by Richard Scheller, previously of Genentech who became Chief Science Officer and Head of Therapeutics in 2015. Pharmaceutical company GlaxoSmithKline (GSK) partnered with 23andME in 2018.
23andMe raises a $249,999,947 series F round from the Wallenberg Foundation, Euclidean Capital, Casdin Capital, Altimeter Capital, Sequoia Capital and Fidelity Management & Research Company.
23andMe raises a $150,000,000 series E round.
23andMe raises a $50,000,000 series D round from Anne Wojcicki, New Enterprise Associates, Sergey Brin, MPM Capital and Yuri Milner.
23andMe raises a $22,000,000 series C round from New Enterprise Associates.
23andMe raises a $12,600,000 series B round from Google and Sergey Brin.
23andMe raises a $9,000,000 series A round from Mohr Davidow Ventures, Google, New Enterprise Associates and Genentech.
23andMe was founded by Anne Wojcicki and Linda Avey.
J. Fah Sathirapongsasuti
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- CompanyA company, abbreviated 'co.', is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.
- Unicorn (finance)A privately held startup company with an evaluation above $1 billion.